Hasten Biopharmaceutical, Backed by CBC, Acquires 14 Celltrion Products

 


CBC Group, the largest healthcare-focused asset management firm in Asia with its headquarters in Singapore, has announced that its subsidiary, Hasten Biopharmaceutical, an innovative biopharmaceutical company, has successfully completed the acquisition of the asset rights for 14 branded products across various countries and regions in Asia from Celltrion, a biopharmaceutical company based in South Korea. This acquisition showcases CBC's distinctive "investor-operator" model, which leverages innovation, extensive industry knowledge, and commercial expertise to assist prominent healthcare companies like Hasten in identifying valuable assets and expanding their presence internationally.


As per the terms of the agreement, Hasten will now hold the Marketing Authorization Holder (MAH) rights for these 14 products in eight countries and regions, including South Korea, Singapore, Thailand, Australia, and China Hong Kong S.A.R. This transaction not only enhances Hasten's product pipeline and distribution network but also signifies its strategic growth across the Pan-Asian region. Specializing in chronic diseases and critical care, Hasten aims to broaden its product offerings through this acquisition, gaining commercial rights to medications for various chronic conditions such as hypertension and diabetes, which include Edarbi, Basen, Actos, Blopress, and Nesina.

More Information https://www.techdogs.com/tech-news/pr-newswire/cbc-backed-hasten-biopharmaceutical-announces-acquisition-of-14-celltrion-legacy-products

Comments

Popular posts from this blog

Aon Unveils $350M Program for Ukraine Recovery

Lion Energy Unveils 10W Solar Panel for Portable Power

AGIA Affinity Sweeps Multiple Marketing Awards at 2023 PIMA Insights Conference